![]() |
|
Featured Link:
10th International Symposium on Blood Substitutes Contents
Interesting Links (top)Most Interesting Picture Credits (top)All picture credits are listed in order of appearance. Intro History Opinions PFCs HBOCs Platelets Website References (top)
Chang TM. Hemoglobin-based red blood cell substitutes. Kim HW, Greenburg AG. Artificial oxygen carriers as red blood cell substitutes: a selected review and current status. Kjellstrom BT. Blood substitutes: where do we stand today? Rudnicke C. Transfusion alternatives. Winslow RM. Current status of blood substitute research: towards a new paradigm. Kim HW, Greenburg AG. Artificial oxygen carriers as red blood cell substitutes: a selected review and current status. Reid, Thomas J. Hb-based oxygen carriers: are we there yet? Alliance Pharmaceutical Corp. Oxygent™ Fact Sheet . 28 March 2005 <http://www.allp.com/Oxygent/ox_fact.htm>. BioSpace. “Alliance Pharmaceutical Corp.” 20 March 1998 . 27 April 2005 . <http://www.biospace.com/company_profile.cfm?CompanyID=1273>. 4/27/05 BioSpace. “Alliance Pharmaceutical Corp. and Beijing Double-Crane Pharmaceutical Co. Ltd. Announce a Memorandum of Understanding Concerning the Development, Licennsins nd Markerting of Oxygent ™ in the People's Republic of China .” PRNewswire-FirstCall. 5 April 2005 . 27 April 2005 . < http://www.biospace.com/news_story.cfm?StoryID=19613620&full=1>. BioSpace. “Alliance Pharmaceutical Corp. and LEO Pharma Modify Exclusivity Agreement Related to the Development and Marketing of Oxygent™ in Europe and Canada .” PRNewswire-FirstCall. 2 March 2005 . 27 April 2005 . <http://www.biospace.com/news_story.cfm?StoryID=19242620&full=1>. BioSpace. “Alliance Pharmaceutical Corp. Announces Change in Senior Executive Status and Provides Updated on Revised Oxygent™ Development Plan Following Feedback From European Regulatory Authorities.” PRNewswire-FirstCall . 6 Oct. 2004 . 27 April 2005 . <http://www.biospace.com/news_story.cfm?StoryID=17583420&full=1>. Business Wire. “Sanguine Provides a Shareholder Update on the Progress of PHER-O2 Testing.” 25 April 2005 . 26 April 2005 . <http://biz.yahoo.com/bw/050425/255030.html?.v=1>. Cohn, Stephen M. MD, FACS. “ Oxygen Therapeutics in Trauma and Surgery.” Journal of Trauma-Injury Infection & Critical Care 54.5 (2003). 28 March 2005 <http://gateway.ut.ovid.com.revproxy.brown.edu/gw1/ovidweb.cgi > FDA Official. “re: blood substitutes.” E-mail to Evan Werlin. 15 April 2005 . Fridey, Joy, MD, "Oxygen carriers as alternatives to red cell transfusion," UpToDate, 2005. Keipert, Peter E., Ph. D. “A Temporary Intravenous Oxygen Carrier: Physical Properties and Developmental Status.” 28 March 2005 <http://www.allp.com/Oxygent/OX_PETER.HTM> Kiral, Richard M., Ph. D., and David P. Evitts. “Development and Properties of Oxycyte: A New Perfluorocarbon Blood Substitute.” 13 Nov. 2002 . 28 March 2005 . <http://www.sybd.com/pages/sybdreport5.html> Kirschman, Ruth Ann BS, RN, C, WHNP. “Finding Alternatives to Blood Transfusion.” Nursing 34.6 (2004). 28 March 2005 <http://www.nursing2004.com/pt/re/nursing/fulltext.00152193-200406000-00046.htm;jsessionid=Cu9wOqabKxAHRs9DNVuVcYG919ZyxCGy6OnDUph9JiSiNJ8alOaQ!-264389797!-949856032!9001!-1>. Kovelenov, A.Yu., B.O.Voitenkov, E.I.Mayevsky, and S.Yu. Pushkin. “ Perspectives of Using Perfluorocarbon Compound in HIV-Infection (Abstract).” 3 rd Baltic Region Conference “Together Against AIDS!”. Final Program (2003). 19 April 2005 . <http://www.perftoran.ru/Eng/modules.php?name=News&file=article&sid=29>. Lexico Publishing Group, LLC. “Surfactant.” 28 April 2005 . <http://dictionary.reference.com/search?q=surfactant>. Loubser, Paul G., MD. “Applied Medical Research & Development ANH Bulletin.” Dec. 1998. 28 April 2005 . <http://www.hematicus.com/Bull10.html>. Maevsky, E.I. “Clinical Results of Perftoran Application: Present and Future (Abstract).” Artificial Blood 11.1 (2003). 19 April 2005 . <http://www.perftoran.ru/Eng/modules.php?name=News&file=article&sid=20>. Nicora, Robert, Richard Kiral, and Douglas Kornbrust. “Nonclinical Safety of Oxycyte-An Intravenous Perfluorocarbon Oxygen Carrier.” 13 Nov. 2002 . 20 April 2005 . <htttp://www.sybd.com/pages/sybdreport8.html>. Riess, Jean G. “Understanding the Fundamentals of Perfluorocarbons and Perfluorocarbon Emulsions Relevant to In Vivo Oxygen Delivery.” Artificial Cells, Blood Substitutes, and Biotechnology: An International Journal 33.1 (2005): 47-63. Robinson, Alicia. “Fake Blood Passes Early Tests.” Los Angeles Times: Costa Mesa Daily Pilot 13 Nov. 2003 . 28 March 2005 < http://www.sybd.com/pages/sybdreport9.html> Sanguine Corp. Sanguine Products 28 March 2005 <http://www.sanguine-corp.com/products.htm>. Sarteschi, Lelio Mario. “Re: Blood Substitutes.” E-mail to Evan Werlin. 25 April 2005 . Synthetic Blood International. “Patients Enrolled in Synthetic Blood International's Phase II Oxycyte Trial .” 18 April 2005 . 26 April 2005 . < http://www.sybd.com/pages/sybdnews2005.html#Anchor-Synthetic-041805.> Zhiburt, Eugene B., and Anna V. Kovalenko. “Perftoran is Reliable Alternative of Blood Transfusion.” Blood Banking and Transfusion Medicine 1.2 (2003). 19 April 2005 . <http://www.perftoran.ru/Eng/modules.php?name=News&file=article&sid=18>. Beauchesne, Pascal (2004) The Design of Blood Substitutes: Oxygen Carriers. BioTeachJournal. Creteur, Sibbald (2000) Hemoglobin Solutions – Not just red blood cell substitutes. Crit Care Med. Fridey, Joy (2004) Oxygen Carriers as Alternatives to Red Cell Transfusion. UpToDate. Kim, Hae Won & Greenburg, A. Gerson (2004) Artificial Oxygen Carriers as Red Blood Cell Substitutes: A Selected Review and Current Status. Artificial Organs . Kim, Hae Won & Greenburg, A. Gerson (2004) Hemoglobin-Based Oxygen Carriers. Critical Care . Reid, Thomas J. (2003) Hb-Based Oxygen Carriers: Are we there yet? Transfusion. Alving BM, Reid TJ, Fratantoni JC, Finlayson JS. Frozen platelets and platelet substitutes in transfusion medicine. Blajchman MA. Substitutes and alternatives to platelet transfusions in thrombocytopenic patients. Choi ES, Nichol JL, Hokom MM, Hornkohl AC, Hunt P. Platelets generated in vitro from proplatelet-displaying human megakaryocytes are functional. Corash L. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes. Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking to the future. Lee DH, Blajchman MA. Novel treatment modalities: new platelet preparations and substitutes. Silberman S. Platelets: preparations, transfusion, modifications, and substitutes. |
|